Marea Therapeutics
South San Francisco, California, United States · Biotechnology, Therapeutics · 200 employees
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. Marea is led by a dynamic team of scientists and company
Funding history
- Funding Round — $65.4M — Jun 2024
Recent signals
- Jan 09, 2025: Launched Marea Therapeutics, Inc. Updates on Corporate Progress and Pipeline with MAR001 for Cardiovascular Disease.
- Dec 19, 2024: Marea Therapeutics Appoints Rebecca Juliano as Chief Development Officer and Max Zeiberg as Senior Vice President, Corporate Development
- Jun 24, 2024: Raised $65.4M
See plans & pricing → Track Marea Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.